Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female subjects between ages of 18-65 years~* Body mass index of 18.0-35.0 kg/m2~* Non-smokers for at least 3 months~* Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine~* Agree to follow the contraception requirements of the trial~* Able to give fully informed written consent.~Exclusion Criteria:~* Positive tests for hepatitis B \& C, HIV~* Severe adverse reaction to any drug~* Drug or alcohol abuse~* Use of over-the-counter medication (with the exception of paracetamol \[acetaminophen\]) during the 7 days before the first dose of trial medication, or prescribed medication during the 28 days before first dose of trial medication~* Any vaccination within 4 weeks before dose of trial medication~* Participation in other clinical trials of unlicensed medicines within the previous 3 months~* Loss of more than 400 mL blood within the previous 3 months~* Vital signs outside the acceptable range~* Clinically relevant abnormal findings at the screening assessment~* Acute or chronic illness~* Clinically relevant abnormal medical history or concurrent medical condition~* Possibility that volunteer will not cooperate~* Females who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ensovibep dose 1 (infusion) (Type: EXPERIMENTAL): None
- ensovibep dose 2 (infusion) (Type: EXPERIMENTAL): None
- ensovibep dose 3 (infusion) (Type: EXPERIMENTAL): None
- placebo (infusion) (Type: PLACEBO_COMPARATOR): None
- ensovibep dose 4 (IV bolus) (Type: EXPERIMENTAL): None
- ensovibep dose 5 (IV bolus) (Type: EXPERIMENTAL): None
- ensovibep dose 6 (SC injection) (Type: EXPERIMENTAL): None
- ensovibep dose 7 (SC injection) (Type: EXPERIMENTAL): None
- ensovibep dose 8 (SC injection) (Type: EXPERIMENTAL): None
- ensovibep dose 9 (SC injection) (Type: EXPERIMENTAL): None
- ensovibep dose 10 (IM injection) (Type: EXPERIMENTAL): None
- ensovibep dose 11 (IM injection) (Type: EXPERIMENTAL): None
- ensovibep dose 12 (IM injection) (Type: EXPERIMENTAL): None
- ensovibep dose 13 (IM injection) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).